-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Alzheon announced the completion of a $50 million Series D financing, which will be used to accelerate the Phase 3 clinical trial APOLLOE4 of its oral investigational therapy ALZ-801 (valiltramiprosate) for the treatment of early Alzheimer's disease, and potential Regulatory applications
ALZ-801 is an oral drug in Phase 3 clinical development that blocks the formation of soluble amyloid oligomers associated with cognitive decline in Alzheimer's disease process potential
In February, the company announced positive biomarker results from a Phase 2 clinical trial of ALZ-801
The results of the phase 2 clinical trial including 80 patients showed that the plasma p-tau181 level in the ALZ-801 group was significantly reduced by 29% (p=0.
In addition to biomarker results, the Phase 2 clinical study also included the Rey Auditory Verbal Learning Test (RAVLT) as a secondary endpoint
Martin Tolar, founder, president and CEO of Alzheon, said: "Alzheon develops differentiated solutions for the treatment and prevention of Alzheimer's disease
References:
References:[1] Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and Expansion of Product Portfolio.
[1] Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and Expansion of Product Portfolio.
Retrieved April 14, 2022, from https:// /en
